Special Issue "Pluripotent Stem Cells for Cardiac Differentiation and Disease Modeling"
Deadline for manuscript submissions: closed (10 November 2021) | Viewed by 7590
Interests: cardiac myocytes; pluripotent stem cells; stem cells; in vitro techniques; human embryonic stem cells; genes
Special Issues, Collections and Topics in MDPI journals
Cardiovascular disease is responsible for the highest mortality rate worldwide and its incidence is expected to increase to epidemic proportions in the coming years and decades. Although current animal and in vitro models have broadened and deepened our insights into cardiac development and disease and their underlying mechanisms, the situation regarding the discovery of new drugs and novel therapeutic approaches is deplorable. There is a clear urgent need for academia as well as industry to create and implement human-based models that accurately mimic cardiovascular disease and have the potential to include patient-to-patient variations. Since the groundbreaking discovery of human-induced pluripotent stem cells (iPSCs), many scientific reports have appeared on the differentiation of specialized cardiac cell types and derivation of patient-derived iPSCs for modeling cardiac disease or for potential therapeutic applications in regenerative medicine.
Despite these recent advances, significant hurdles need to be overcome before we are able to take full advantage of the benefits of patient-derived stem cells. How can we accomplish cardiovascular cell cultures and multicellular vascularized cardiac tissues with a similar level of maturation, organization, and function as observed in vivo – if possible or required at all? How can we mimic monogenic, polygenic, or multifactorial human cardiac diseases, or important aspects or phases of cardiac disease? Current advances in various technologies, including stem cell differentiation, genetic modification, tissue engineering or organoid formation, microfabrication, and microfluidics (organs-on-chip), which are needed to close the gap between human in vitro models and the patient, will be discussed in this Special Issue.
Prof. Dr. Robert Passier
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cardiac disease modeling
- Tissue engineering
- Cardiac differentiation
- Human pluripotent stem cells
- Personalized medicine
- Regenerative medicine
- Assay development
- Drug testing/discovery